Analysis of the publicly available Microarray Innovations in Leukemia (MILE) study (GSE13159) further validated the upregulation of CDK6 in patients with BCR::ABL1+ ALL (Supplementary Fig. S1A) [32, 33]. This evidence concerns the gene CDK6 and acute lymphoblastic leukemia.